
## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4692464/publications.pdf Version: 2024-02-01



FENC WE

#	Article	IF	CITATIONS
1	Long non-coding RNA HOTAIR promotes tumor cell invasion and metastasis by recruiting EZH2 and repressing E-cadherin in oral squamous cell carcinoma. International Journal of Oncology, 2015, 46, 2586-2594.	3.3	211
2	Diagnostic and prognostic value of circulating miR-21 for cancer: A systematic review and meta-analysis. Gene, 2014, 533, 389-397.	2.2	139
3	High-mobility group nucleosome-binding protein 1 acts as an alarmin and is critical for lipopolysaccharide-induced immune responses. Journal of Experimental Medicine, 2012, 209, 157-171.	8.5	130
4	IL-8, a novel messenger to cross-link inflammation and tumor EMT via autocrine and paracrine pathways (Review). International Journal of Oncology, 2016, 48, 5-12.	3.3	122
5	Long noncoding RNA HOTAIR involvement in cancer. Tumor Biology, 2014, 35, 9531-9538.	1.8	119
6	Neurotensin/IL-8 pathway orchestrates local inflammatory response and tumor invasion by inducing M2 polarization of Tumor-Associated macrophages and epithelial-mesenchymal transition of hepatocellular carcinoma cells. OncoImmunology, 2018, 7, e1440166.	4.6	105
7	Dendritic cell-activated cytokine-induced killer cells enhance the anti-tumor effect of chemotherapy on non-small cell lung cancer in patients after surgery. Cytotherapy, 2009, 11, 1076-1083.	0.7	102
8	Interleukin-6 Trans-Signaling Pathway Promotes Immunosuppressive Myeloid-Derived Suppressor Cells via Suppression of Suppressor of Cytokine Signaling 3 in Breast Cancer. Frontiers in Immunology, 2017, 8, 1840.	4.8	92
9	Anti-CD47 Antibody As a Targeted Therapeutic Agent for Human Lung Cancer and Cancer Stem Cells. Frontiers in Immunology, 2017, 8, 404.	4.8	73
10	The role of toll-like receptor 4 in tumor microenvironment. Oncotarget, 2017, 8, 66656-66667.	1.8	71
11	Expression of TNFR2 by regulatory T cells in peripheral blood is correlated with clinical pathology of lung cancer patients. Cancer Immunology, Immunotherapy, 2015, 64, 1475-1485.	4.2	66
12	High Indoleamine 2,3-Dioxygenase Is Correlated With Microvessel Density and Worse Prognosis in Breast Cancer. Frontiers in Immunology, 2018, 9, 724.	4.8	63
13	Expression signature, prognosis value, and immune characteristics of Siglec-15 identified by pan-cancer analysis. Oncolmmunology, 2020, 9, 1807291.	4.6	63
14	Suppression of T cells by myeloid-derived suppressor cells in cancer. Human Immunology, 2017, 78, 113-119.	2.4	62
15	A novel MDSC-induced PD-1 <sup>â^'</sup> PD-L1 <sup>+</sup> B-cell subset in breast tumor microenvironment possesses immuno-suppressive properties. Oncolmmunology, 2018, 7, e1413520.	4.6	61
16	New insight on the correlation of metabolic status on 18F-FDG PET/CT with immune marker expression in patients with non-small cell lung cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1127-1136.	6.4	59
17	The Alarmin HMGN1 Contributes to Antitumor Immunity and Is a Potent Immunoadjuvant. Cancer Research, 2014, 74, 5989-5998.	0.9	56
18	Identification of a three-miRNA signature as a blood-borne diagnostic marker for early diagnosis of lung adenocarcinoma. Oncotarget, 2016, 7, 26070-26086.	1.8	52

#	Article	IF	CITATIONS
19	Expression of TLR4 in Non-Small Cell Lung Cancer Is Associated with PD-L1 and Poor Prognosis in Patients Receiving Pulmonectomy. Frontiers in Immunology, 2017, 8, 456.	4.8	51
20	Phosphoglyceric acid mutase-1 contributes to oncogenic mTOR-mediated tumor growth and confers non-small cell lung cancer patients with poor prognosis. Cell Death and Differentiation, 2018, 25, 1160-1173.	11.2	51
21	NTS/NTR1 co-expression enhances epithelial-to-mesenchymal transition and promotes tumor metastasis by activating the Wnt/β-catenin signaling pathway in hepatocellular carcinoma. Oncotarget, 2016, 7, 70303-70322.	1.8	46
22	Plasma miR-324-3p and miR-1285 as diagnostic and prognostic biomarkers for early stage lung squamous cell carcinoma. Oncotarget, 2016, 7, 59664-59675.	1.8	45
23	Profiling the dynamic expression of checkpoint molecules on cytokine-induced killer cells from non-small-cell lung cancer patients. Oncotarget, 2016, 7, 43604-43615.	1.8	45
24	The alarmin functions of high-mobility group proteins. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2010, 1799, 157-163.	1.9	41
25	Transcription Factor E2F1 Suppresses Dendritic Cell Maturation. Journal of Immunology, 2010, 184, 6084-6091.	0.8	40
26	Autologous Cytokine-Induced Killer Cells Improves Overall Survival of Metastatic Colorectal Cancer Patients: Results From a Phase II Clinical Trial. Clinical Colorectal Cancer, 2016, 15, 228-235.	2.3	38
27	IDO inhibits T-cell function through suppressing Vav1 expression and activation. Cancer Biology and Therapy, 2009, 8, 1402-1408.	3.4	33
28	Exhausted T cells and epigenetic status. Cancer Biology and Medicine, 2020, 17, 923-936.	3.0	32
29	Upregulated expression of indoleamine 2, 3-dioxygenase in CHO cells induces apoptosis of competent T cells and increases proportion of Treg cells. Journal of Experimental and Clinical Cancer Research, 2011, 30, 82.	8.6	31
30	Soluble Toll-like receptor 4 is a potential serum biomarker in non-small cell lung cancer. Oncotarget, 2016, 7, 40106-40114.	1.8	31
31	Human umbilical cord mesenchymal stem cells delivering sTRAIL home to lung cancer mediated by MCP-1/CCR2 axis and exhibit antitumor effects. Tumor Biology, 2016, 37, 8425-8435.	1.8	28
32	Alarminâ€induced cell migration. European Journal of Immunology, 2013, 43, 1412-1418.	2.9	26
33	Myeloid-derived suppressor cells regulate the immunosuppressive functions of PD-1â^'PD-L1+ Bregs through PD-L1/PI3K/AKT/NF-κB axis in breast cancer. Cell Death and Disease, 2021, 12, 465.	6.3	25
34	Matrix metalloproteinase 13: a potential intermediate between low expression of microRNA-125b and increasing metastatic potential of non–small cell lung cancer. Cancer Genetics, 2015, 208, 76-84.	0.4	24
35	A new perspective: Exploring future therapeutic strategies for cancer by understanding the dual role of B lymphocytes in tumor immunity. International Journal of Cancer, 2019, 144, 2909-2917.	5.1	24
36	Significantly different immunological score in lung adenocarcinoma and squamous cell carcinoma and a proposal for a new immune staging system. Oncolmmunology, 2020, 9, 1828538.	4.6	20

#	Article	lF	CITATIONS
37	Predictive value of K-ras and PIK3CA in non-small cell lung cancer patients treated with EGFR-TKIs: a systemic review and meta-analysis. Cancer Biology and Medicine, 2015, 12, 126-39.	3.0	20
38	Single-cell profiling of immune cells after neoadjuvant pembrolizumab and chemotherapy in IIIA non-small cell lung cancer (NSCLC). Cell Death and Disease, 2022, 13, .	6.3	20
39	Herceptin Enhances the Antitumor Effect of Natural Killer Cells on Breast Cancer Cells Expressing Human Epidermal Growth Factor Receptor-2. Frontiers in Immunology, 2017, 8, 1426.	4.8	17
40	Seroprevalence of Neutralizing Antibodies against Human Adenovirus Type-5 and Chimpanzee Adenovirus Type-68 in Cancer Patients. Frontiers in Immunology, 2018, 9, 335.	4.8	17
41	T-cell receptor gene therapy targeting melanoma-associated antigen-A4 by silencing of endogenous TCR inhibits tumor growth in mice and human. Cell Death and Disease, 2019, 10, 475.	6.3	16
42	Morphine-3-glucuronide upregulates PD-L1 expression <i>via</i> TLR4 and promotes the immune escape of non-small cell lung cancer. Cancer Biology and Medicine, 2021, 18, 155-171.	3.0	16
43	PD-1/PD-L1 Axis, Rather Than High-Mobility Group Alarmins or CD8+ Tumor-Infiltrating Lymphocytes, Is Associated With Survival in Head and Neck Squamous Cell Carcinoma Patients Who Received Surgical Resection. Frontiers in Oncology, 2018, 8, 604.	2.8	15
44	Memory stem T cells generated by Wnt signaling from blood of human renal clear cell carcinoma patients. Cancer Biology and Medicine, 2019, 16, 109.	3.0	15
45	TIM-3 and CEACAM1 are Prognostic Factors in Head and Neck Squamous Cell Carcinoma. Frontiers in Molecular Biosciences, 2021, 8, 619765.	3.5	15
46	Prediction of immune-related adverse events in non-small cell lung cancer patients treated with immune checkpoint inhibitors based on clinical and hematological markers: Real-world evidence. Experimental Cell Research, 2022, 416, 113157.	2.6	15
47	Adoptive Cellular Therapy (ACT) for Cancer Treatment. Advances in Experimental Medicine and Biology, 2016, 909, 169-239.	1.6	14
48	Prognostic Value of the Neo-Immunoscore in Renal Cell Carcinoma. Frontiers in Oncology, 2019, 9, 439.	2.8	13
49	Neurotensin, a Novel Messenger to Cross-Link Inflammation and Tumor Invasion via Epithelial-Mesenchymal Transition Pathway. International Reviews of Immunology, 2014, 35, 1-11.	3.3	12
50	The hOGG1 Ser326Cys polymorphism contributes to digestive system cancer susceptibility: evidence from 48 case–control studies. Tumor Biology, 2015, 36, 1029-1038.	1.8	12
51	High-mobility group nucleosome-binding protein 1 is a novel clinical biomarker in non-small cell lung cancer. Tumor Biology, 2015, 36, 9405-9410.	1.8	12
52	Efficiency of Cytokine-Induced Killer Cells in Combination with Chemotherapy for Triple-Negative Breast Cancer. Journal of Breast Cancer, 2018, 21, 150.	1.9	12
53	Prognosis significance of indoleamine 2, 3-dioxygenase, programmed death ligand-1 and tumor-infiltrating immune cells in microenvironment of breast cancer. International Immunopharmacology, 2020, 84, 106506.	3.8	12
54	Lung cancer-associated mesenchymal stem cells promote tumor metastasis and tumorigenesis by induction of epithelial–mesenchymal transition and stem-like reprogram. Aging, 2021, 13, 9780-9800.	3.1	11

#	Article	IF	CITATIONS
55	Immunoactivative role of indoleamine 2,3‑dioxygenase in gastric cancer cells in vitro. Molecular Medicine Reports, 2011, 4, 169-73.	2.4	9
56	Nociceptin Receptor Is Overexpressed in Non-small Cell Lung Cancer and Predicts Poor Prognosis. Frontiers in Oncology, 2019, 9, 235.	2.8	9
57	Expression level of PD-L1 is involved in ALDH1A1-mediated poor prognosis in patients with head and neck squamous cell carcinoma. Pathology Research and Practice, 2020, 216, 153093.	2.3	9
58	Single-Cell Sequencing Reveals the Transcriptome and TCR Characteristics of pTregs and in vitro Expanded iTregs. Frontiers in Immunology, 2021, 12, 619932.	4.8	9
59	Prognostic value of pretreatment inflammatory biomarkers in advanced lung adenocarcinoma patients receiving first-line pemetrexed/platinum doublet. Tumor Biology, 2017, 39, 101042831770163.	1.8	8
60	Vaccination with Allogeneic GM-CSF Gene-Modified Lung Cancer Cells: Antitumor Activity Comparing with that Induced by Autologous Vaccine. Cancer Biotherapy and Radiopharmaceuticals, 2007, 22, 790-798.	1.0	7
61	Comprehensive insights into the effects and regulatory mechanisms of immune cells expressing programmed death-1/programmed death ligand 1 in solid tumors. Cancer Biology and Medicine, 2020, 17, 626-639.	3.0	7
62	Efficient antiproliferative and antiangiogenic effects on human ovarian cancer growth by gene transfer of attenuated mutants of Shiga-like toxin I. International Journal of Gynecological Cancer, 2008, 18, 677-691.	2.5	5
63	Expression and purification of recombinant human interleukin-18 protein using a yeast expression system. Protein Expression and Purification, 2008, 62, 44-48.	1.3	5
64	Enhanced activation of human dendritic cells by silencing SOCS1 and activating TLRs simultaneously. Cancer Immunology, Immunotherapy, 2012, 61, 1653-1661.	4.2	5
65	EZH2 identifies the precursors of human natural killer cells with trained immunity. Cancer Biology and Medicine, 2021, 18, 1021-1039.	3.0	5
66	Relationship and prognostic significance of IL-33, PD-1/PD-L1, and tertiary lymphoid structures in cervical cancer. Journal of Leukocyte Biology, 2022, 112, 1591-1603.	3.3	5
67	Primary tumor standardized uptake value (SUVmax) measured on 18F-FDG PET/CT and mixed NSCLC components predict survival in surgical-resected combined small-cell lung cancer. Journal of Cancer Research and Clinical Oncology, 2020, 146, 2595-2605.	2.5	3
68	The prognostic landscape of genes and infiltrating immune cells in cytokine induced killer cell treated-lung squamous cell carcinoma and adenocarcinoma. Cancer Biology and Medicine, 2021, 18, 0-0.	3.0	2
69	Survival benefit and toxicity profile of adjuvant icotinib for patients with EGFR mutation-positive non-small cell lung carcinoma: a retrospective study. Translational Lung Cancer Research, 2020, 9, 2401-2410.	2.8	2
70	Trained Immunity of IL-12-, IL-15-, and IL-18-Induced CD3+CD56+ NKT-Like Cells. Journal of Oncology, 2022, 2022, 1-14.	1.3	1
71	Recombinant bovine pancreatic trypsin inhibitor protects the liver from carbon tetrachloride-induced chronic injury in rats. Pharmaceutical Biology, 2013, 51, 1298-1303.	2.9	0
72	Randomized, Multicenter, Open-Label Trial of Autologous Cytokine-Induced Killer Cell Immunotherapy Plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. SSRN Electronic Journal, 0, , .	0.4	0

	Feng V	VEI	
#	Article	IF	CITATIONS
73	Single-cell profiling of immune cells associated with response to neoadjuvant chemoimmunotherapy in IIIA non-small cell lung cancer (NSCLC) Journal of Clinical Oncology, 2022, 40, e20584-e20584.	1.6	Ο